Aim: The aim of this analysis was to test the additive metabolic benefit of sequential addition of SGLT-2i followed by GLP1-RA along with metformin in a real-life scenario.

Material & Methods: A retrospective real world observational case note study conducted in two diabetes care centres in India analyzed the first 60 consecutive T2D patients who could afford this therapy and had not achieved their glycaemic target on metformin and SGLT2i were added either Dulaglutide or Liraglutide and followed up for 13 weeks.

Results: Both liraglutide and dulaglutide proved to be an excellent add on to metformin and SGLT-2 inhibitor. Liraglutide had an additional significant impact on systolic blood pressure reduction as well as larger proportion achieved target HBA1C in contrast to the dulaglutide.

Conclusion: In this retrospective study in Indian type 2 diabetic patients poorly controlled with metformin and SGLT-2 inhibitor we found a meaningful impact of adding a GLP1-RA on all metabolic parameters. There were additional advantages seen with liraglutide as far achieving target HBA1C of less than 7% and also on the quantum of weight loss and systolic blood pressure reduction.

Liraglutide and dulaglutide in addition to SGLT-2i and metformin in Indian T2DM: a retrospective observational study